Late-Stage Active Oncology Drug Developers | An Overview
June 22, 2024
Exosomes are cell-derived nanovesicles, which are usually 50-150 nm in diameter and are involved in the intercellular transportation of materials....
Microbiome is an emerging player in cancer drug development. Recent research findings elicit varied roles of human gut microbiome, both...
Antibody Drug Conjugates (ADCs) are therapeutic entities with monoclonal antibody (mAb) backbone linked to cytotoxic drugs and are designed to...
Oncolytic Viruses (OVs) based therapies uses natural or genetically modified viruses to specifically infect and lyse cancer cells but does not...
Bispecific (bsAbs) & Multispecific antibodies are a diverse family of antibody constructs that recognize two or more epitopes. These candidates...
AstraZeneca plc - Oncology Drug Development Deals and Alliances Insights provides you with a comprehensive data and trend analysis of...
Astellas Pharma - Oncology Drug Development Deals and Alliances Insights provides you with a comprehensive data and trend analysis of...
AbbVie, Inc (ABBV) - Oncology Drug Development Deals and Alliances Profile provides you comprehensive data and trend analysis of the...
NK is the abbreviation of Natural Killer, and its Chinese name is natural killer cell. Due to the pan-specific...
Read moreupdated.. easy.. precise... complete...
Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.
LEARN MORE »
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.